2019-06-052019-06-052009PIGINI, Mara Agi; ÁVILA, Marcos Pereira; MAGACHO, Leopoldo. Efeitos da ibopamina 2% tópica nos resultados da campimetria visual computadorizada. Arquivos Brasileiros de Oftalmologia, São Paulo, v. 72, n. 3, p. 365-369, 2009.0004-2749http://repositorio.bc.ufg.br/handle/ri/17612Purpose: To evaluate the influence of 2% ibopamine eye drops on the results of computerized visual field exams. Me- thods: Normal volunteers from CEROF-UFG were selected, with no variance in the ophthalmologic examination that could affect the visual field test. The volunteers underwent compu- terized visual field test before and after dilation with 2% ibo- pamine eye drop or cyclopentolate, with a minimum interval of three days between them and in a random order. Global indices and number of altered points were compared between the groups. Results: Thirty eyes of 30 normal individuals were selected. There was no statistically significant difference on Mean Deviation (MD) before and after dilation with ibopa- mine (MD: -1.05 ± 0.26 dB vs. -1.47 ± 0.20 dB, P=0.08). Ho- wever, after cycloplegia (MD: -3.19 ± 0.29 dB), there was a significant difference on MD (P<0.001 for both ibopamine and pre-dilation). No significant difference was detected in the Pattern Standard Deviation when comparing ibopamine with pre-dilation and cycloplegia values, but it was statistically significant comparing pre-dilation to cycloplegia (P=0.04). The number of altered points in the Pattern Deviation graphic were not significant comparing all pairs. There was a sta- tistically significant difference in the number of altered points in the total deviation graphic before dilation and after cyclo- plegia (n: 8.86 ± 1.51 vs. 25.72 ± 2.96 points, P<0.001), and comparing cycloplegia with ibopamine (ibopamine: 9.75 ± 1.85 points, P<0.001). Conclusion: Ibopamine 2% eye drops seem to not modify the results of visual field tests in normal individuals.porAcesso AbertoCiclopentolato/administração & dosagemPerimetriaGlaucoma/diagnósticoPressão intraocular/efeitos de drogasHipertensão ocularCyclopentolate/administration & dosageGlaucoma/diagnosisPerimetryOcular hypertensionIntraocular pressure/drug effectsArtigo10.1590/S0004-27492009000300016